University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Curr Opin Virol. 2017 Jun;24:25-30. doi: 10.1016/j.coviro.2017.03.016. Epub 2017 Apr 14.
Chikungunya virus (CHIKV) is a re-emerging alphavirus that caused massive outbreaks of Chikungunya fever in several countries and regions in Africa, Asia and more recently in Central and South America. An acute CHIKV infection is usually associated with fever and arthritis and it is rarely fatal. However, 15-60% of patients suffer from chronic polyarthralgia for weeks, months or even for several years after the acute infection. There are currently no vaccines or antivirals available for the prevention or treatment of CHIKV infections. The development of potent and safe antivirals for prophylaxis (e.g., during travel to CHIKV-endemic regions) and treatment of CHIKV infections is urgently needed. We here review some of the recently reported CHIKV inhibitors, both directly-acting and host-targeting compounds.
基孔肯雅热病毒（CHIKV）是一种重新出现的甲病毒，在非洲、亚洲和最近的中美洲和南美洲的几个国家和地区引发了大规模的基孔肯雅热疫情。急性 CHIKV 感染通常伴有发热和关节炎，很少致命。然而，15-60%的患者在急性感染后数周、数月甚至数年遭受慢性多关节炎。目前尚无预防或治疗 CHIKV 感染的疫苗或抗病毒药物。迫切需要开发有效的、安全的抗病毒药物用于预防（例如，在前往基孔肯雅热流行地区旅行期间）和治疗 CHIKV 感染。在这里，我们回顾了一些最近报道的 CHIKV 抑制剂，包括直接作用和宿主靶向化合物。
